AOA Dx earlier today announced that they have been accepted to Y Combinator’s 2021 summer cohort and have closed a $2.5 million seed round to develop AKRIVIS GD, a liquid biopsy test that is set to revolutionize the future of ovarian cancer diagnostics. AOA Dx has been working in close collaboration with world renowned cancer researcher Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University.
“We are incredibly excited to continue our journey towards improving the future of healthcare for women. Currently, 80% of ovarian cancer patients are diagnosed at stage III or IV, resulting in a very low 5 year survival rate.” said Oriana Papin-Zoghbi, CEO and Co-Founder. “AOA’s technology is set to transform ovarian cancer diagnostics by detecting the disease earlier. We are thrilled to be amongst the very small group of Y Combinator backed companies and work with some of the most talented individuals and investors in the startup world.”
You can learn more about AOA Dx’s recent seed round on the company’s blog.
